Free Trial

Dyne Therapeutics (DYN) News Today

Dyne Therapeutics logo
$13.78 -0.13 (-0.93%)
Closing price 02/18/2025 04:00 PM Eastern
Extended Trading
$13.78 0.00 (0.00%)
As of 02/18/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned an average rating of "Buy" from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, ten have given a buy recommendation an
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Should You Sell?
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low - Here's Why
Dyne Therapeutics, Inc. stock logo
abrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)
abrdn plc acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 25,803 shares of the company's stock, valued at approximately $608,000. A number of other hedge funds and other institution
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Trading Down 5% - Should You Sell?
Dyne Therapeutics (NASDAQ:DYN) Shares Down 5% - Time to Sell?
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Trading 7% Higher - Here's What Happened
Dyne Therapeutics (NASDAQ:DYN) Shares Up 7% - Should You Buy?
Dyne Therapeutics, Inc. stock logo
Jennison Associates LLC Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)
Jennison Associates LLC lowered its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 10.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,211,915 shares of the company's stock after selling 135,0
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase - What's Next?
Dyne Therapeutics (NASDAQ:DYN) Sees Unusually-High Trading Volume - Here's Why
Dyne Therapeutics: Moving Forward On 2 Key Fronts
Dyne Therapeutics, Inc. stock logo
Guggenheim Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday.
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from Brokerages
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned a consensus recommendation of "Buy" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Here's What Happened
Dyne Therapeutics (NASDAQ:DYN) Sets New 52-Week Low - Time to Sell?
Dyne Therapeutics receives FDA Fast Track designation for DYNE-101
Dyne Enjoys Fast Track Status for New Treatment
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low - What's Next?
Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.7% - Here's Why
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7% - Should You Sell?
Dyne Therapeutics (DYN) Gets a Buy from RBC Capital
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics' (DYN) Outperform Rating Reaffirmed at Royal Bank of Canada
Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday.
RBC remain buyers of Dyne Therapeutics after DM1 and DMD data
Dyne Therapeutics, Inc. stock logo
Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday.
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday.
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's Why
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's Why
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.7% - Here's Why
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 3.7% - Here's Why
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% - What's Next?
Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% - Here's What Happened
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from Analysts
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a s
Dyne Therapeutics, Inc. stock logo
Geode Capital Management LLC Acquires 84,760 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)
Geode Capital Management LLC lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,859,413 shares of the company's stock after
Dyne Therapeutics, Inc. stock logo
Barclays PLC Raises Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)
Barclays PLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 162.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 207,309 shares of the company's stock after acquiring an additional 128,246 shares
Dyne Therapeutics, Inc. stock logo
Wellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)
Wellington Management Group LLP lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 81.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,661 shares of
Dyne Therapeutics, Inc. stock logo
Franklin Resources Inc. Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)
Franklin Resources Inc. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 21.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,342,500 shares of the company's stock a
Dyne Therapeutics, Inc. stock logo
State Street Corp Raises Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)
State Street Corp increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,641,859 shares of the compa
Dyne Therapeutics initiated with an Outperform at Baird
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics (NASDAQ:DYN) Upgraded to "Strong-Buy" at Raymond James
Raymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday.
Get Dyne Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.

DYN Media Mentions By Week

DYN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DYN
News Sentiment

0.20

0.44

Average
Medical
News Sentiment

DYN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DYN Articles
This Week

3

6

DYN Articles
Average Week

Get Dyne Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:DYN) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners